suppression of tumorigenicity 7 likeGenealiases: FAM4B · ST7R · STLR
Q-omics provides the consensus-scored ST7L profile across patient tissues and cancer cell-line models. ST7L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ST7L is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ST7L RNA expression shows 20,828 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, THCA, and ACC as cancer lineages where ST7L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST7L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST7L survival associations across molecular data types. ST7L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST7L RNA expression–survival associations across cancer types. High ST7L expression shows unfavorable associations in ACC, LIHC, LGG and KICH, but favorable associations in OV and BRCA. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for ST7L RNA expression.
This table summarizes ST7L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ST7L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST7L shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, COAD and CHOL. The THCA box plot shows higher ST7L RNA expression in normal versus tumor tissue (log2 FC = −0.595, t-test p < 0.001).
This table shows molecular features associated with ST7L in patient tissues and cancer cell lines. In patient samples, ST7L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ST7L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
